SSRIs show efficacy over placebo only in the most severely depressed patients
This article has no abstract so we have provided the first paragraph of the full text.
Selective serotonin reuptake inhibitors (SSRIs) have been approved for the treatment of depression but have failed to show clear clinical efficacy versus placebo when examined in meta-analyses. Kirsch et al. have proposed that analysis of patients as a single group might obscure a treatment effect in those who are most likely to benefit from these agents, such as individuals with extremely severe depression.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.